Management of treatment resistant obsessive-compulsive disorder. Algorithms for pharmacotherapy

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Treatment-resistant obsessive-compulsive disorder (TRD) affects a significant portion of patients (40-50%) who do not respond to standard SRI therapy.
• Assessing the adequacy of prior SRI trials (clomipramine or SSRIs) is crucial before considering alternative treatments.

Purpose of the Study:

• To review and outline treatment strategies for patients with TRD who have not responded to adequate SRI trials.
• To discuss the evidence base for various augmentation and switching strategies in managing refractory OCD.

Main Methods:

• Literature review of existing studies on treatment-resistant OCD.
• Analysis of evidence for intravenous medication, cognitive behavioral therapy (CBT), augmentation, and drug switching strategies.
• Evaluation of double-blind, placebo-controlled studies and preliminary data.

Main Results:

• Intravenous clomipramine is a viable option, with evidence supporting its efficacy, though data for citalopram are lacking.
• Cognitive behavioral therapy, specifically exposure and response prevention, is recommended when available, despite limited data.
• Augmentation with pindolol, risperidone, or olanzapine has shown efficacy in double-blind studies, while other agents lack robust evidence.
• Switching between different SRIs or to venlafaxine, sumatriptan, or inositol requires further research.

Conclusions:

• For treatment-resistant OCD, clinicians can consider intravenous therapy, CBT, or augmentation strategies.
• Augmentation is often preferred over switching due to potentially faster response times.
• Further research is essential to establish the efficacy of novel monotherapy agents for refractory OCD.